PE20599A1 - Pirazoles como inhibidores de fosfolipasa secretora no pancreatica humana a2 - Google Patents

Pirazoles como inhibidores de fosfolipasa secretora no pancreatica humana a2

Info

Publication number
PE20599A1
PE20599A1 PE1997001083A PE00108397A PE20599A1 PE 20599 A1 PE20599 A1 PE 20599A1 PE 1997001083 A PE1997001083 A PE 1997001083A PE 00108397 A PE00108397 A PE 00108397A PE 20599 A1 PE20599 A1 PE 20599A1
Authority
PE
Peru
Prior art keywords
alkyl
pancreatic
optionally substituted
phenyl
compounds
Prior art date
Application number
PE1997001083A
Other languages
English (en)
Inventor
Peter Jeremy Doman
Gary Alan Hite
Edward David Mihelich
Tulio Suarez
Stuart Edmund Willetts
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20599A1 publication Critical patent/PE20599A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIEREN A COMPUESTOS DE FORMULA (I), EN DONDE: R1 ES FENILO, ISOQUINOLIN-3-ILO, PIRAZINILO, PIRIDIN-2-ILO OPCIONALMENTE SUSTITUIDO EN LA POSICION 4 CON ALQUILO C1-C4, ALCOXILO C1-C4, CN, (CH2)nCONH2, EN DONDE n ES 0-2; R2 ES NAFTILO, TIOFENO OPCIONALMENTE SUSTITUIDO CON 1 A 3 HALOGENOS o FENILO OPCIONALMENTE SUSTITUIDO CON 1 A 3 RADICALES ALQUILO C1-C4, CN, HALOGENO, NO2, CO2-ALQUILO C1-C4, CF3; R3 ES H, FENILO OPCIONALMENTE SUSTITUIDO, PIRIDILO, NAFTILO, QUINOLINILO, ALQUILO C1-C4-TIAZOLILO; SON COMPUESTOS (I) PREFERIDOS 3-(2-CLORO-6-METILFENILSULFONILAMINO)-4-(2-(4-ACETAMIDO)PIRIDIL)-5-(3-(4-FLUOROFENOXI)BENCILTIO)-(1H)-PIRAZOL Y 3-(2,6-DICLOROFENILSULFONILAMINO)-4-(2-(4-ACETAMIDO)PIRIDIL)-5-(3-(4-FLUOROFENOXI)BENCILTIO)-(1H)-PIRAZOL. TAMBIEN SE REFIERE AL PROCEDIMIENTO DE PREPARACION. LOS COMPUESTOS DE FORMULA (I) ACTUAN INHIBIENDO LA LIBERACION DE ACIDOS GRASOS PRODUCIDOS POR LA FOSFOLIPASA SECRETORA NO PANCREATICA HUMANA A2 (sPLA2), SIENDO UTILES EN EL TRATAMIENTO DEL SHOCK SEPTICO, SINDROME DE DIFICULTAD RESPIRATORIA EN ADULTOS, ENTRE OTROS
PE1997001083A 1996-12-04 1997-12-01 Pirazoles como inhibidores de fosfolipasa secretora no pancreatica humana a2 PE20599A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3321696P 1996-12-04 1996-12-04

Publications (1)

Publication Number Publication Date
PE20599A1 true PE20599A1 (es) 1999-03-05

Family

ID=21869147

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997001083A PE20599A1 (es) 1996-12-04 1997-12-01 Pirazoles como inhibidores de fosfolipasa secretora no pancreatica humana a2

Country Status (22)

Country Link
US (1) US5972972A (es)
EP (1) EP0846687B1 (es)
JP (1) JP2002515053A (es)
KR (1) KR20000057366A (es)
AR (1) AR010743A1 (es)
AT (1) ATE203985T1 (es)
AU (1) AU5365598A (es)
BR (1) BR9713993A (es)
CA (1) CA2274048A1 (es)
CO (1) CO4910169A1 (es)
DE (1) DE69706027T2 (es)
DK (1) DK0846687T3 (es)
ES (1) ES2160897T3 (es)
HK (1) HK1011865A1 (es)
HU (1) HUP0000292A3 (es)
ID (1) ID18983A (es)
IL (1) IL130202A0 (es)
PE (1) PE20599A1 (es)
PT (1) PT846687E (es)
TW (1) TW432051B (es)
WO (1) WO1998024437A1 (es)
ZA (1) ZA9710878B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087381A (en) * 1997-05-22 2000-07-11 G. D. Searle & Company Pyrazole derivatives as p38 kinase inhibitors
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
KR20010042307A (ko) 1998-03-31 2001-05-25 시오노 요시히코 피롤로[1,2-ａ]피라진 ｓＰＬＡ2 억제제
EP1085021A4 (en) 1998-05-21 2003-01-08 Shionogi & Co DERIVATIVES OF PYRROLO 1,2-B] PYRIDAZINE, WITH INHIBITOR EFFECT ON SPLA 2?
ATE329619T1 (de) 1998-10-14 2006-07-15 Shionogi & Co Spla2-inhibitoren zur behandlung von ischämischen reperfusionsschäden
AU6015600A (en) 1999-07-19 2001-02-05 Shionogi & Co., Ltd. Tricyclic compounds having spla2-inhibitory activities
JP4636522B2 (ja) 1999-08-02 2011-02-23 塩野義製薬株式会社 ｓＰＬＡ２阻害作用を有する三環式化合物
WO2001014378A1 (fr) 1999-08-23 2001-03-01 Shionogi & Co., Ltd. DERIVES DE PYRROLOTRIAZINE A ACTIVITES INHIBANT sPLA¿2?
ES2171116B1 (es) * 2000-04-14 2003-08-01 Esteve Quimica Sa Procedimiento para la obtencion de derivados de (((piridil sustituido)metil)tio)bencimidazol.
AU2001267823A1 (en) 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Compounds exhibiting x-type spla2 inhibiting effect
US6967200B2 (en) 2000-06-29 2005-11-22 Shionogi & Co., Ltd. Remedies for cirrhosis
TWI314457B (es) 2001-03-19 2009-09-11 Shionogi & Co
US7076539B2 (en) * 2001-07-30 2006-07-11 Hewlett-Packard Development Company, L.P. Network connectivity establishment at user log-in
WO2003101177A2 (en) * 2002-06-04 2003-12-11 Sequenom, Inc. Diagnosing predisposition to fat deposition and therapeutic methods for reducing fat deposition and treatment of associated conditions
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
AU2003248793A1 (en) * 2002-06-27 2004-01-19 Sequenom, Inc Diagnosing predisposition to fat deposition and associated condition
AU2003248794B2 (en) * 2002-06-27 2007-10-04 Harkness Pharmaceuticals, Inc. Therapeutic methods for reducing fat deposition and treating associated conditions
CN101925588B (zh) * 2008-01-25 2014-01-15 先正达参股股份有限公司 用作杀虫剂的2-氰基苯基磺酰胺衍生物
EP2424521A4 (en) 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE
CN105017134A (zh) * 2015-07-26 2015-11-04 陈吉美 一种4-吡啶丙烯酸的制备方法
LT3752510T (lt) 2018-02-15 2023-04-11 Vertex Pharmaceuticals Incorporated Makrocikliniai junginiai kaip cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatoriai, jų farmacinės kompozicijos, jų panaudojimas cistinės fibrozės gydymui ir jų gamybos būdas
TW202115092A (zh) 2019-08-14 2021-04-16 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
TW202120517A (zh) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
JP2022544383A (ja) 2019-08-14 2022-10-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒモジュレータの結晶形態
US20230373939A1 (en) * 2020-10-07 2023-11-23 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3616681A1 (de) * 1986-05-16 1987-11-19 Bayer Ag 1-aralkylpyrazole
JPH02229169A (ja) * 1989-03-01 1990-09-11 Takeda Chem Ind Ltd ピラゾロン誘導体
JPH02229168A (ja) * 1989-03-01 1990-09-11 Takeda Chem Ind Ltd ピラゾロン誘導体
DK0465913T3 (da) * 1990-07-10 1997-10-20 Ishihara Sangyo Kaisha Diaminotrifluormethylpyridinderivater, fremgangsmåder til fremstilling deraf og phospholipase-A2-inhibitor indeholdende samme
EP0539034A1 (en) * 1991-10-22 1993-04-28 Konica Corporation A novel photographic cyan coupler
US5541213A (en) * 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5500439A (en) * 1993-12-09 1996-03-19 Alteon Inc. Aminopyrazoles
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation

Also Published As

Publication number Publication date
ID18983A (id) 1998-05-28
DK0846687T3 (da) 2001-10-08
CA2274048A1 (en) 1998-06-11
JP2002515053A (ja) 2002-05-21
AU5365598A (en) 1998-06-29
HUP0000292A2 (hu) 2001-04-28
KR20000057366A (ko) 2000-09-15
EP0846687A1 (en) 1998-06-10
HUP0000292A3 (en) 2002-01-28
ES2160897T3 (es) 2001-11-16
CO4910169A1 (es) 2000-04-24
US5972972A (en) 1999-10-26
EP0846687B1 (en) 2001-08-08
ATE203985T1 (de) 2001-08-15
TW432051B (en) 2001-05-01
DE69706027T2 (de) 2002-03-14
WO1998024437A1 (en) 1998-06-11
DE69706027D1 (de) 2001-09-13
HK1011865A1 (en) 1999-07-23
PT846687E (pt) 2001-12-28
ZA9710878B (en) 1999-06-03
BR9713993A (pt) 2000-02-08
AR010743A1 (es) 2000-07-12
IL130202A0 (en) 2000-06-01

Similar Documents

Publication Publication Date Title
PE20599A1 (es) Pirazoles como inhibidores de fosfolipasa secretora no pancreatica humana a2
AR002722A1 (es) Compuestos de amida y urea triciclicos, composicion farmaceutica que los contiene, uso de dichos compuestos para la fabricacion de un medicamento parainhibir el desarrollo anormal de las celulas
PE20020506A1 (es) Derivados de pirazol fusionados como inhibidores de la proteina cinasa
PE20090477A1 (es) Derivados de oxazol como inhibidores de los canales de sodio
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
PE20100737A1 (es) Nuevos compuestos
PE20081135A1 (es) Derivados que contienen sulfamoilo y sus usos
PE20060166A1 (es) Derivados de amida como inhibidores de proteinas de apoptosis (iap)
PE20040987A1 (es) Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf)
NO921141L (no) Indolderivater, fremgangsmaate for deres fremstilling og anvendelse derav
BR9103433A (pt) Derivados de 4-benzil-isoxazol
PE59999A1 (es) Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona-8-sustituidos
ATE319440T1 (de) Antidiabetische mittel
PE20100741A1 (es) COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38
AR037901A1 (es) Beta-amino-alfa-cianoacrilatos
PE20020467A1 (es) Compuestos de 1,4-dihidropiridina como antagonistas de bradicinina
ES2132284T3 (es) Derivados de carbamato de 2-(piperidin-4-il, piridin-4-il y tetrahidropiridin-4-il)-benzofurano-7, su preparacion y su uso como inhibidores de acetilcolinesterasa.
PE20030718A1 (es) Lactamas como antagonistas de taquiquininas
CO5150219A1 (es) Inhibidores de metaloproteasa que contiene alquenilo y alque nilo que son efectivos en el tratamiento de condiciones ca- racterizadas por actividad excesiva de estas enzimas
CO4990932A1 (es) Derivados de 2,1,3-benzotiadiazol y proceso para su preparacion
DK69790D0 (da) Heterocykliske forbindelser, deres fremstilling af anvendelse
PE29798A1 (es) Acetidinas
PE20050587A1 (es) Derivados de diazindol-dicarbonilo-piperazinilo como agentes antivirales
PE20070535A1 (es) Derivados de 3-feniluracilo para desecar y/o desfoliar cultivos resistentes a glifosato
AR008287A1 (es) Composicion herbicida que comprende compuestos de pirazol sustituidos y metodo de aplicacion de los mismos

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed